|
2024
|
Invention
|
Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musc... |
|
|
Invention
|
Composition and method for the diagnosis and treatment of iron-related disorders. Provided herein... |
|
|
G/S
|
dietitian services in connection with clinical trials |
|
|
Invention
|
Methods for treating hcv.
The present invention features interferon-free therapies for the treat... |
|
|
Invention
|
Methods of treating pediatric patients with upadacitinib.
The present disclosure is directed to ... |
|
|
Invention
|
Methods of treating pediatric patients with upadacitinib. The present disclosure is directed to m... |
|
|
Invention
|
Assay for evaluating tau propagation. in vivoin vivo assays for evaluating tau propagation activi... |
|
|
Invention
|
Medicine container, method of assembling the container, and method of manufacturing the container... |
|
|
Invention
|
Pump, motor and assembly for beneficial agent delivery.
Pump includes a motor, a cam shaft coupl... |
|
|
Invention
|
Clostridium botulinum serotype a neurotoxin (bont/a) sequence variants.
Provided herein are comp... |
|
|
Invention
|
Clostridium botulinum neurotoxin serotype a compositions.
The present disclosure relates to Clos... |
|
|
Invention
|
Clostridium botulinum serotype a neurotoxin (bont/a) sequence variants. Clostridium botulinumClos... |
|
|
Invention
|
Clostridium botulinum neurotoxin serotype a compositions. Clostridium botulinumClostridium botuli... |
|
2023
|
Invention
|
Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor.
The presen... |
|
|
Invention
|
Anti-papp-a antibodies and methods of use thereof. Provided herein are anti-PAPP-A antibodies. Al... |
|
|
Invention
|
Anti-papp-a antibodies and methods of use thereof.
Provided herein are anti-PAPP-A antibodies. A... |
|
|
Invention
|
Anti-egfr antibody-drug conjugates.
The present disclosure relates to anti-Epidermal Growth Fact... |
|
|
Invention
|
Methods of treating acute myeloid leukemia and managing cytopenia.
Provided herein are methods f... |
|
|
Invention
|
Dosing regimens for elagolix.
The present invention relates to dosing regimens for GnRH receptor... |
|
|
Invention
|
Devices and methods for delivering a beneficial agent to a user.
Drug delivery reservoir cassett... |
|
|
Invention
|
Methods of administering elagolix.
The present disclosure relates to the use of GnRH receptor an... |
|
|
Invention
|
Pyrrolidine main protease inhibitors as antiviral agents.
Pyrrolidine main protease inhibitors a... |
|
|
Invention
|
Pyrrolidine main protease inhibitors as antiviral agents. Pyrrolidine main protease inhibitors ar... |
|
|
Invention
|
Cocrystals of upadacitinib.
The disclosure relates to cocrystals of solid state forms of (3S,4R)... |
|
|
Invention
|
Suppressors of site iq electron leak and uses thereof. Described herein, inter alia, are suppress... |
|
|
Invention
|
Methods of treating hidradenitis suppurativa.
The present disclosure is directed to methods for ... |
|
|
Invention
|
Methods of treating hidradenitis suppurativa. The present disclosure is directed to methods for t... |
|
|
Invention
|
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases.
Disclo... |
|
|
Invention
|
N-methyl-4-(quinolin-2-yl)pyridin-2-amine compounds. The present disclosure provides compounds of... |
|
|
Invention
|
Anti-sez6 antibody drug conjugates.
The present disclosure provides SEZ6 antibody drug conjugate... |
|
|
Invention
|
Anti-sez6 antibody drug conjugates. The present disclosure provides SEZ6 antibody drug conjugates... |
|
|
G/S
|
Eye drops |
|
|
Invention
|
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
Disclo... |
|
|
G/S
|
Ophthalmic preparations, namely, lubricant eye drops |
|
|
Invention
|
Treating spondyloarthritic and psoriatic conditions with upadacitinib.
Provided are methods for ... |
|
|
Invention
|
Macrocyclic mcl-1 inhibitors and methods of use.
The present disclosure provides for compounds o... |
|
|
Invention
|
Methods of treating systemic lupus erythematosus.
The present disclosure is directed to methods ... |
|
|
Invention
|
Single-chain trail-receptor agonist proteins.
Provided herein are specific TRAIL receptor agonis... |
|
|
Invention
|
Anti-egfr antibody drug conjugates.
The invention relates to anti-Epidermal Growth Factor Recept... |
|
|
G/S
|
providing information about medical clinical trials, namely, information in the field of improvin... |
|
|
G/S
|
Providing medical information in the field of improving diversity and inclusion in clinical resea... |
|
|
Invention
|
Modulators of the integrated stress pathway.
Provided herein are compounds, compositions, and me... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of glaucoma |
|
|
Invention
|
Pyrimidines for degrading bruton's tyrosine kinase.
The present invention provides for compounds... |
|
|
Invention
|
Solid pharmaceutical compositions for treating hcv.
The present invention features solid pharmac... |
|
|
G/S
|
Providing a website featuring information in the field of the diagnosis and pharmaceutical treatm... |
|
2022
|
Invention
|
Subcutaneously administered treatments for advanced parkinson's disease.
The present disclosure ... |
|
|
G/S
|
Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders |
|
|
G/S
|
Pharmaceutical substances and preparations for the treatment of oncological diseases and disorders. |
|
|
G/S
|
pharmaceutical substances and preparations for the treatment of oncological diseases and disorders |
|
|
Invention
|
Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including t... |
|
|
G/S
|
Education services, namely, conducting classes, workshops, training seminars, and in-person discu... |
|
|
G/S
|
Education services, namely conducting classes, workshops, training seminars, and discussion forum... |
|
2021
|
Invention
|
Extended release upadacitinib formulations.
The disclosure describes extended release solid dosa... |
|
|
G/S
|
medical services; providing medical information; providing healthcare information to nurse practi... |
|
|
G/S
|
Administration of a discount program for medical patients featuring product savings programs, pro... |
|
2020
|
G/S
|
Charitable services, namely, patient assistance program to provide drugs free of charge to low-in... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of viral, namely herpes, hepatitis, ... |
|
|
G/S
|
pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musc... |
|
|
G/S
|
Pharmaceutical drug mail order services; pharmaceutical services, namely, processing online presc... |
|
|
G/S
|
mail order and online retail pharmacy services; pharmaceutical services, namely, processing of on... |
|
|
G/S
|
Providing medical information to patients and medical professionals in the form of reports in the... |
|
|
Invention
|
Container cap |
|
|
G/S
|
Printed matter, namely, pamphlets, brochures, newsletters, handouts, magazines, annual reports, b... |
|
2019
|
G/S
|
pharmaceutical preparations for the treatment of hepatitis C |
|
|
G/S
|
Providing medical information, namely, information regarding medical conditions, treatments and p... |
